|Bid||9.40 x 0|
|Ask||9.42 x 0|
|Day's range||9.23 - 9.70|
|52-week range||4.93 - 24.10|
|Beta (5Y monthly)||3.23|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.35|
Depsite its dreadful performance over the last two years, investors may still hold out a smudge of hope that things will turn around for Canada-based marijuana producer Aurora Cannabis (NASDAQ: ACB). After all, a cursory glance at its historical stock prices indicates that Aurora did make some investors wealthy in the past. Since it started selling medical cannabis in the first quarter of 2016, Aurora's share price rose by as much as 2,400% through early 2018.
Cannabis producer Aurora Cannabis (NASDAQ: ACB) reported its fourth-quarter results in September. While the numbers weren't all that surprising -- sales were lackluster and the business remains unprofitable -- the one thing that stood out was the company's claim that it is again on track to post a profit.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Aurora Cannabis Inc...